Suppression of elevated aminotransferase activity in liver disease by vigabatrin

Journal of Paediatrics and Child Health

Volumn 34, Issue 4, 1998, Pages 395-397

  Williams, A ^a   Sekaninova, S ^a   Coakley, J ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Alanine aminotransferase; Alpers disease; Liver disease; Vigabatrin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; VIGABATRIN; 4 AMINOBUTYRIC ACID; DRUG DERIVATIVE; ENZYME INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC ERROR; DISEASE COURSE; HUMAN; INBORN ERROR OF METABOLISM; INFANT; LIVER DISEASE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEIZURE; DRUG ANTAGONISM; ENZYMOLOGY; FATALITY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; SCHILDER DISEASE;

ALANINE TRANSAMINASE; ANTICONVULSANTS; DIFFUSE CEREBRAL SCLEROSIS OF SCHILDER; ENZYME INHIBITORS; FATAL OUTCOME; GAMMA-AMINOBUTYRIC ACID; HUMANS; INFANT; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; SEIZURES; VIGABATRIN;

EID: 0032130685     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.1998.00249.x     Document Type: Article

References (12)

1. Young DS. Effects of Drugs on Clinical Laboratory Tests, 3rd edn. AACC Press, 1990; 3-12.
2. Remy C Beaumont D. Efficacy and safety of vigabatrin in the longterm treatment of refractory epilepsy. Br. J. Clin. Pharmac. 1989; 27: 125S-129S.
3. Hulsman J. The influence of vigabatrin on ALAT activity measurements. Clin. Chem. 1993; 39: 1142 (abstr.).
4. Ryan MF, Samy A, Young J. Vigabatrin causes profound reduction in serum alanine transaminase activity. Ann. Clin. Biochem. 1996; 33: 257-8.
5. Olsen R, Horder M. Decreased alanine aminotransferase activity in serum of man during gamma-acetylenic-GABA treatment. Scand. J. Clin. Lab. Invest. 1980; 40: 393-5.
6. Shoffner JM, Wallace DC. Oxidative phosphorylation diseases. In: Scriver C R et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 7th edn. Mcgraw Hill, New York, 1995; 1535-609.
7. Schechter PJ. Biochemical and therapeutic effect of GABA-transaminase inhibition: clinical studies with gamma vinyl gaba. Neuropharmacology 1984; 23: 865-6.
8. Meldrum BS. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br. J. Clin. Pharmac. 1989; 27: 3S-11S.
9. Lippert B, Metcalf BW, Jung MJ, Casara P. 4 Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Euro. J. Biochem. 1977; 74: 441-5.
10. Okumura H, Omote M, Takeshita S. In vitro effects of the novel anti-epileptic agent vigabatrin on alanine aminotransferase and aspartate aminotransferase activities in rat serum. Arzneimittelforschung 1996; 46: 459-62.
11. Williams A, Goldsmith R, Coakley J. Profound suppression of plasma alanine aminotransferase activity in children taking vigabatrin. Aust. NZ J. Med. 1993; 23: 65.
12. Coakley J, Williams A, Sekaninova S. Inhibition of plasma alanine aminotransferase activity by vigabatrin. Proceedings of the XVI international congress of clinical chemistry. The Association of Clinical Biochemists, 1996; 69 (abstr.).